Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Transplantation of endothelial progenitor cells attenuates pulmonary fibrosis via IFITM3-containing exosomes
Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin
Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin
View: Text | PDF
Research Article Pulmonology Vascular biology

Transplantation of endothelial progenitor cells attenuates pulmonary fibrosis via IFITM3-containing exosomes

  • Text
  • PDF
Abstract

Endothelial progenitor cells (EPCs) are critical for vascular regeneration after injury. However, their role in pulmonary fibrosis (PF) remains unclear. Here, we identified a previously unrecognized population of lung capillary EPCs coexpressing c-KIT and FOXF1 (capEPCs) in adult human and mouse lungs. capEPCs were significantly reduced in lungs from patients with PF and in bleomycin-injured mice, implicating loss of this regenerative endothelial population in disease pathogenesis. Transplantation of donor capEPCs attenuated experimental PF, improved survival, reduced collagen deposition, and restored lung function. Donor capEPCs engrafted into the lung microcirculation of bleomycin-injured mice. Single-cell RNA sequencing identified interferon-induced transmembrane protein 3 as a highly enriched transcript in capEPCs. Conditioned media from IFITM3-overexpressing EPCs or recombinant IFITM3 enhanced endothelial proliferation and angiogenesis while suppressing TGF-β1–induced fibroblast activation in vitro. IFITM3 was found in capEPC-derived exosomes. Treatment with IFITM3-containing exosomes recapitulated the therapeutic effects of capEPC transplantation by improving endothelial function, inhibiting fibroblast activation, increasing animal survival, reducing lung fibrosis, and restoring lung function. Together these findings identified capEPC deficiency as a feature of PF and demonstrated that IFITM3-containing exosomes promoted vascular repair. Restoration of capEPC regenerative function or delivery of IFITM3-enriched exosomes may represent a promising therapeutic strategy for human PF.

Authors

Ying-Wei Lan, Jonathan Do, Wen Gao, Zicheng Deng, Xiaomei Xia, Enhong Li, Jillian Kash, Gautam Verma, Angara Sureshbabu, Kenneth S. Knox, Ross M. Bremner, Nicholas E. Banovich, Vladimir V. Kalinichenko, Tanya V. Kalin

×

Figure 3

Transplantation of capEPCs improves survival and lung function in bleomycin-injured mice.

Options: View larger image (or click on image) Download as PowerPoint
Transplantation of capEPCs improves survival and lung function in bleomy...
(A) Top: Schematic of the FACS sorting strategy to isolate donor capEPCs (Foxf1+Kit+) and control Foxf1–Kit+ ECs from Foxf1-GFP;CAG-tdTomato reporter mice. Bottom: Experimental timeline. Right: qRT-PCR confirmed higher Foxf1 mRNA in capEPCs (n = 4). (B) Transplantation of capEPCs improved survival of bleomycin-injured mice. Numbers in parentheses indicate surviving mice/total mice per group. (C) Body weight recovery after bleomycin injury was improved in mice treated with capEPCs compared with mock-treated mice (BLM-mock) or mice treated with Foxf1–Kit+ ECs (BLM-Foxf1–Kit+). *Comparison with BLM-mock; #comparison with BLM-Foxf1–Kit+ ECs. (D) Arterial oxygen saturation on day 21 was increased after capEPC transplantation (control, n = 3; BLM-mock, n = 7; BLM-Foxf1–Kit+ ECs, n = 4; BLM-capEPCs, n = 4). (E) Lung resistance (Rrs) and elastance (Ers) measured by flexiVent show improved respiratory mechanics in capEPCs-treated mice (control, n = 3; BLM-mock, n = 5; BLM-Foxf1–Kit+ ECs, n = 4; BLM-capEPCs, n = 4). (F) Transplantation of capEPCs increased inspiratory capacity (IC), static compliance (Cst), and pressure-volume loop area, indicating enhanced lung compliance and elasticity (n = 3–5 mice per group). Data are presented as mean ± SD. Body weight recovery in C was analyzed by 2-way ANOVA with Greenhouse-Geisser correction (#P < 0.05, ##P < 0.01). Other comparisons were performed using 1-way ANOVA with Fisher’s LSD test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts